Search

everythinglearnresearchcommunity

for

Search:↓

Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.

Rituximab can cause skin issues, but baricitinib may help improve them.

Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.

Baricitinib improved hair loss and arthritis in a lupus patient.

Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Ixekizumab effectively treats generalized pustular psoriasis.

Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.

Budesonide alone is less effective than standard treatment for autoimmune hepatitis.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Ocrelizumab may cause pancreatitis in some patients.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

Bimekizumab can improve scarring alopecia in severe psoriasis.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

An antibiotic called co-trimoxazole can effectively treat autoimmune diseases.

Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.

Infliximab can trigger lupus-like symptoms in Crohn's disease patients.

Belimumab may cause hair loss in lupus patients.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

Rituximab improved her dermatomyositis better than usual treatments.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

Rituximab effectively managed a difficult case of juvenile lupus with complications, reducing the need for steroids.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.